The PLASMA Act would modify Medicare's drug pricing rules to provide a temporary exemption for plasma-derived products, which are medicines made from human blood or plasma. Under current law, manufacturers must provide substantial discounts on drugs covered by Medicare Part D, but this bill would allow plasma-derived products already on the market to be exempt from the full discount requirements during a phase-in period. The discount percentage that manufacturers must provide would vary depending on whether Medicare beneficiaries have reached their out-of-pocket spending threshold in a given year. This legislation specifically affects seniors and people with disabilities who rely on plasma-derived medicines, as well as the manufacturers of these products. The bill was introduced in July 2024 and referred to the Senate Committee on Finance but does not specify an end date for the phase-in period or dedicate any particular funding.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.